Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 1,020,000 shares, a decrease of 63.6% from the September 30th total of 2,800,000 shares. Approximately 4.7% of the company’s stock are short sold. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $2.00 price target on shares of Cardio Diagnostics in a research report on Tuesday, August 27th.

Cardio Diagnostics Stock Performance

Shares of CDIO stock traded up $0.01 on Friday, hitting $0.22. 497,110 shares of the stock traded hands, compared to its average volume of 887,071. Cardio Diagnostics has a 1-year low of $0.17 and a 1-year high of $3.56. The company’s fifty day moving average is $0.28 and its 200 day moving average is $0.52.

Cardio Diagnostics (NASDAQ:CDIO) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.07. Cardio Diagnostics had a negative net margin of 22,358.43% and a negative return on equity of 312.97%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.13 million. As a group, equities research analysts predict that Cardio Diagnostics will post -0.55 EPS for the current year.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.